Human evidence record · Mazdutide
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight (GLORY-1)
At week 48: -11.00% (4 mg), -14.01% (6 mg), +0.30% placebo; ≥15% loss in 35.7%, 49.5%, 2.0%.
Quick read
Human evidence record
What this study tells us
Participants were assigned to comparison groups by chance, usually with placebo and/or blinding to reduce bias. This is a strong design for testing cause and effect, but the population, duration and endpoints still limit what can be concluded.
Who was studied?
Chinese adults with overweight or obesity
How many?
n=610
What happened?
At week 48: -11.00% (4 mg), -14.01% (6 mg), +0.30% placebo; ≥15% loss in 35.7%, 49.5%, 2.0%.
What stops us overclaiming?
Single-country population; cross-trial comparisons with other incretins are indirect.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
At week 48: -11.00% (4 mg), -14.01% (6 mg), +0.30% placebo; ≥15% loss in 35.7%, 49.5%, 2.0%.
Study details
Study designRandomized, double-blind, placebo-controlled trial
PhasePhase 3
PopulationChinese adults with overweight or obesity
Sample size610
RouteSubcutaneous
Regimen / exposure4 mg or 6 mg once weekly
Duration48 weeks
ComparatorPlacebo
Primary endpoint / questionPercent body-weight change
Safety resultGI events most common and mostly mild-moderate; discontinuation 1.5%, 0.5%, 1.0%.
Key limitationsSingle-country population; cross-trial comparisons with other incretins are indirect.
Registry / identifierNCT05607680